Eli Lilly and Co. (NYSE:LLY) – Equities research analysts at Jefferies Group issued their Q3 2016 earnings estimates for Eli Lilly and in a note issued to investors on Thursday. Jefferies Group analyst J. Holford anticipates that the firm will post earnings per share of $0.98 for the quarter. Jefferies Group has a “Buy” rating and a $105.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2019 earnings at $5.61 EPS.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.86. The firm had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $0.90 EPS.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Several other research analysts also recently commented on LLY. Leerink Swann reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Sunday, June 26th. Credit Suisse Group AG restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, June 28th. BMO Capital Markets restated a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 27th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research report on Friday, July 29th. Finally, Argus raised their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $97.06.

Eli Lilly and (NYSE:LLY) traded down 0.69% on Friday, hitting $79.45. The stock had a trading volume of 1,356,558 shares. Eli Lilly and has a 12-month low of $67.88 and a 12-month high of $88.16. The company has a market capitalization of $84.03 billion, a PE ratio of 34.25 and a beta of 0.17. The company has a 50 day moving average of $79.70 and a 200 day moving average of $77.73.

A number of hedge funds have recently added to or reduced their stakes in LLY. Eaton Vance Management boosted its stake in Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock worth $433,009,000 after buying an additional 2,307,920 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock valued at $159,402,000 after buying an additional 1,880,800 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in shares of Eli Lilly and during the second quarter valued at approximately $104,345,000. Janus Capital Management LLC boosted its stake in shares of Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock valued at $789,162,000 after buying an additional 1,377,814 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock valued at $4,979,889,000 after buying an additional 1,350,329 shares during the last quarter. Institutional investors own 74.96% of the company’s stock.

In related news, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the sale, the insider now directly owns 1,300 shares in the company, valued at approximately $108,108. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $82.94, for a total transaction of $17,002,700.00. Following the completion of the sale, the insider now owns 125,775,804 shares of the company’s stock, valued at $10,431,845,183.76. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.